Cargando…
A Baseline Analysis of Regulatory Review Timelines for ANVISA: 2013–2016
BACKGROUND: The Brazilian health regulatory agency (Agência Nacional de Vigilância Sanitária, ANVISA) has embarked on transformational initiatives to fulfill its mandate to provide timely access to safe, effective, and quality therapeutics. A new Brazilian law was enacted to provide the agency with...
Autores principales: | Patel, Prisha, Cerqueira, Daniela Marreco, Santos, Gustavo Mendes Lima, de Lima Soares, Renata, Sousa, Varley Dias, Liberti, Lawrence, McAuslane, Neil |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7704494/ https://www.ncbi.nlm.nih.gov/pubmed/32519282 http://dx.doi.org/10.1007/s43441-020-00169-5 |
Ejemplares similares
-
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017) -
Quality of medicines: Deficiencies found by Brazilian Health Regulatory Agency (ANVISA) on good manufacturing practices international inspections
por: Geyer, Andrea Renata Cornelio, et al.
Publicado: (2018) -
An evaluation of the Caribbean regulatory system centralized assessment process for medicines submitted 2017–2018 using the OpERA methodology
por: Liberti, Lawrence, et al.
Publicado: (2020) -
Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020) -
To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
por: Kühler, Thomas Christian, et al.
Publicado: (2019)